4-(1-methoxymethylpropoxy)-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(1-methoxymethylpropoxy)-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine
• 英文别名: 4-(1-Methoxybutan-2-yloxy)-3,6-dimethyl-1-(2,4,6-trimethylphenyl)pyrazolo[3,4-b]pyridine
• 化学式: C₂₂H₂₉N₃O₂
• 分子量: 367.491
• InChiKey: QQETTZGPQWCPMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  49.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-chloro-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine 、 1-甲氧基-2-丁醇 以 四氢呋喃 、 甲醇 、 氯仿 为溶剂， 生成 4-(1-methoxymethylpropoxy)-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine
  参考文献：
  名称：

  Bicyclic compounds

  摘要：

  这项发明涉及到以下公式中的化合物，其中A、B、R3、R4、R5和R7的定义如下，并且涉及它们在治疗与压力相关的疾病中的用途。

  公开号：

  US06248753B1

文献信息

• New uses for corticotropin releasing factor (CRF) antagonists
  申请人：PFIZER INC.

  公开号：EP0773023A1

  公开（公告）日：1997-05-14

  A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula    or a pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.

  一种治疗、预防或抑制心血管或心脏相关疾病（如中风、高血压、心动过速和充血性心力衰竭）、骨质疏松症、早产、心理社交侏儒症、压力诱发发热、溃疡、腹泻、术后肠梗阻和与心理病理障碍和压力相关的结肠过敏反应的方法，包括向需要此类治疗的哺乳动物（包括人类）中，给予化合物的治疗有效量，该化合物的结构式如下：其中A、B、D、E、Y、Z、R3、R4和R5的定义如本文所述，或其药学上可接受的盐。
• New uses for corticotropin releasing factor antagonists
  申请人：——

  公开号：US20010000340A1

  公开（公告）日：2001-04-19

  A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula 1 or pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R 3 , R 4 , and R 5 are as defined herein.

  一种治疗、预防或抑制选自心血管或心脏相关疾病（如中风、高血压、心动过速和充血性心力衰竭）、骨质疏松症、早产、心理社交侏儒症、应激性发热、溃疡、腹泻、术后肠梗阻和与心理病理障碍和应激有关的结肠过敏反应的方法，包括向需要该治疗的哺乳动物，包括人类，投与化合物1或其药学上可接受的盐的治疗有效量，其中A、B、D、E、Y、Z、R3、R4和R5如本文所定义。
• Combinations of CRF antagonists and renin-angiotensin system inhibitors
  申请人：Pfizer Products Inc.

  公开号：EP1059100A2

  公开（公告）日：2000-12-13

  The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.

  本发明涉及使用促肾上腺皮质激素释放因子（CRF）拮抗剂和肾素-血管紧张素系统（RAS）抑制剂达到治疗效果的组合物和方法，治疗效果包括但不限于动物（最好是哺乳动物，包括人类或伴侣动物）的充血性心力衰竭或高血压。
• Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
  申请人：Pfizer Products Inc.

  公开号：EP1040831A2

  公开（公告）日：2000-10-04

  A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.

  一种预防猝死的方法，包括向哺乳动物（包括人类）施用治疗有效量的促肾上腺皮质激素释放因子拮抗剂。
• Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm
  申请人：Pfizer Products Inc.

  公开号：EP1082960A2

  公开（公告）日：2001-03-14

  A corticotropin releasing factor (CRF) antagonist is administered to treat a condition selected from the group consisting of: c)disorders that can be treated by altering circadian rhythm; and d)depression, further wherein a second compound for treating depression is administered, the second compound for treating depression having an onset of action that is delayed with respect to that of the CRF antagonist.

  一种促肾上腺皮质激素释放因子（CRF）拮抗剂用于治疗选自以下组别的疾病： c)可通过改变昼夜节律来治疗的疾病；以及 d)抑郁症，其中还施用了治疗抑郁症的第二种化合物，治疗抑郁症的第二种化合物的起效时间比CRF拮抗剂的起效时间延迟。